Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Conference Coverage (AACR)
Antisense Therapy Targets Cancer Angiogenesis
May 26th, 1997
Antisense oligodeoxynucleotides (ODNs) targeting the angiogenic molecule, angiogenin (Ang), inhibit the establishment and metastatic spread of tumors in vivo. Angiogenesis is critical to the growth of solid tumors and the development of metastasis. Interference with the process of tumor-induced angiogenesis has the potential to be an effective therapy for both primary and metastatic cancers. Currently, about nine angiogenic agents are being evaluated in clinical trials for the treatment of several angiogenesis-dependent diseases. To develop additional angiogenesis inhibitors for cancer therapy, James W. Fett and colleagues from the Harvard Medical...
Source: Cancer Weekly (1997-05-26)
|
